Type Public Industry Biotechnology CEO John F. Thero CPA (2014–) Founded 1993 | Traded as NASDAQ: AMRN Products Vascepa (AMR-101) Number of employees 50 | |
 | ||
Website www.amarincorp.com
www.vascepa.com Stock price AMRN (NASDAQ) US$ 3.37 +0.05 (+1.36%)27 Feb, 11:03 AM GMT-5 - Disclaimer Headquarters Dublin, Republic of Ireland | ||
Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Contents
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval. competing against GlaxoSmithKline's Lovaza.
History
Amarin Corporation was founded in 1993 or 1999. In 2002, the company suffered losses worth $37 million, 2003 losses exceeded $19 million. As of 2005 it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.
In December 2007, Amarin acquired Ester Neurosciences Limited for 8.1 million USD. In 2011 CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.
Vascepa
Amarin's only product is Vascepa, an approved prescription grade Omega-3 fatty acid drug (Ethyl eicosapentaenoic acid) to treat hypertriglyceridemia. Vascepa's clinical-data trials were the MARINE and ANCHOR studies.
In November 2010, Amarin's MARINE study, which was to treat patients with very high triglycerides (>500 mg/dL), showed Vascepa decreased triglycerides. Unlike Vascepa's competitor Lovaza, which can raise median LDL-C from 40% to 50%, Vascepa did not significantly increase the median LDL-C.
In April 2011, Amarin's ANCHOR study which treated patients with high triglycerides (200 mg/dL to less than 500 mg/dL), Vascepa decreased LDL-C. The studies showed that Vascepa reduced triglyceride levels and other lipid and inflammation biomarkers, including Apo-B, non-HDL-C, Total-Cholesterol, VLDL-C, Lp-PLA2, and hs-CRP.
In July 2012, Vascepa (AMR-101) received FDA-approval. competing against GlaxoSmithKline's Lovaza. Unlike Lovaza Vascepa was approved for patients with triglycerides of 200 mg/dL to less than 500 mg/dL.
On 10/16/2013 after FDA's ADCOM panel had voted 9-2 against recommending to expand Vascepa's label for treatment of cardiovascular disease, shares dropped over 60%. As of 02/01/2015 their stock price had not recovered.
In March 2016, after losing a court case, the FDA agreed to allow some off-label marketing.
Executives
Management Team (July 2012) :
Board of Directors
As of July 2012 :